Platinum, Palladium...
Health Care: Health Services
Trius Therapeutics Inc. (TSRX: NASDAQ)
$8.47 -0.16 | -1.85%
06/19/13 - 11:10 AM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 27.18M | 41.01M | 8.03M | 5.02M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | -902.00K |
| Gross Operating Profit | 27.18M | 41.01M | 8.03M | 5.92M |
| Selling, General, and Administrative Expenses | 15.40M | 11.34M | 5.41M | 4.13M |
| Research & Development | 69.02M | 49.50M | 23.32M | 23.05M |
| Operating Income before D & A (EBITDA) | -57.23M | -19.83M | -20.69M | -21.26M |
| Depreciation & Amortization | 1.42M | 1.12M | 522.00K | 902.00K |
| Interest Income | 33.00K | 21.00K | 8.00K | 36.00K |
| Other Income - Net | 3.27M | 1.56M | 712.00K | -26.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -55.35M | -19.37M | -20.50M | -22.16M |
| Interest Expense | 0.00 | 0.00 | 3.89M | 524.00K |
| Pre-Tax Income | -55.35M | -19.37M | -24.38M | -22.68M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -53.93M | -18.25M | -23.86M | -22.68M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -53.93M | -18.25M | -23.86M | -22.68M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -53.93M | -18.25M | -23.86M | -22.68M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-53.93M | -18.25M | -23.86M | -22.68M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -53.93M | -18.25M | -23.88M | -22.71M |
| Basic EPS from Continuing Ops. | -1.42 | -0.69 | -2.36 | -1.71 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.42 | -0.69 | -2.36 | -1.71 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.42 | -0.69 | -2.36 | -1.71 |
| Basic Normalized Net Income/Share | -1.42 | -0.69 | -2.36 | -1.71 |
| EPS fr Continuing Ops. | -1.42 | -0.69 | -2.36 | -1.71 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.42 | -0.69 | -2.36 | -1.71 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.42 | -0.69 | -2.36 | -1.71 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.42 | -0.69 | -2.36 | -1.71 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with TSRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserAshley
- ContributorUnder-$10 Setting Up To Tra...
- ContributorStocks Under-$10 Moving Hig...
Latest TSRX Headlines from TheStreet
- Trius Therapeutics Announces Publication Of Antibiotic Safety Study In Antimicrobial Agents And Chemotherapy 06.12.13 | 08:06 am
- Commit To Buy Trius Therapeutics At $5, Earn 11.1% Annualized 06.06.13 | 01:06 pm
- Trius Appoints Matthew Onaitis As General Counsel 06.03.13 | 04:06 pm
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tap 05.22.13 | 07:05 am
- Trius Announces Notice Of Allowance Of U.S. Patent Application Related To Tedizolid Phosphate Combination With Daptomycin 05.13.13 | 08:05 am
- Trius Therapeutics Reports First Quarter 2013 Financial Results 05.07.13 | 04:05 pm
- Cramer's Top Stock Picks: BRK.B FB TSRX 05.04.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan (Correct) 05.03.13 | 07:05 pm
- Trius Therapeutics Presents Clinical Data On Experimental Antibiotic Tedizolid At ECCMID Meeting 04.29.13 | 08:04 am
- Trius Therapeutics To Present Experimental Antibiotic Study Results At ECCMID Meeting 04.23.13 | 08:04 am
Press Releases for TSRX
- Trius Announces Issuance Of Key U.S. Patent For Torezolid Phosphate - PR Newswire 10.25.10 | 04:10 pm
- Trius To Present At San Diego Biotechnology Network Event - PR Newswire 10.22.10 | 04:10 pm
- Trius To Present At 7th Anti-Infectives Partnering And Deal-Making Summit - PR Newswire 10.06.10 | 04:10 pm
- Trius To Participate In Antibiotics Panel Discussion At Citi's 5th Annual Biotech Day - PR Newswire 10.04.10 | 08:10 am
- Trius Reports New Findings On Mechanisms Of Antibiotic Resistance In MRSA - PR Newswire 09.13.10 | 04:09 pm
- Trius To Present At The Stifel Nicolaus Healthcare Conference - PR Newswire 09.13.10 | 08:09 am
- Trius Therapeutics To Present Data From Drug Development Programs At ICAAC - PR Newswire 09.07.10 | 04:09 pm
- Trius Therapeutics Initiates Phase 3 Program Of Oral Torezolid Phosphate For The Treatment Of ABSSSI - PR Newswire 08.30.10 | 08:08 am
Partner Headlines for TSRX
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13) - Seeking Alpha 05.05.13 | 06:05 am
- Oppenheimer Reiterates Outperform Rating, $12 PT on Trius Therapeutics on 4Q12 EPS - Benzinga 03.13.13 | 01:03 pm
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Who Is Paying Attention To MRSA? - Seeking Alpha 10.23.12 | 09:10 am
- The Company You Keep Speaks Volumes: Novabay And Trius - Seeking Alpha 10.09.12 | 09:10 am
- Big Pharma Abandons Antibiotics: An Opening For Small Biotech - Seeking Alpha 05.13.12 | 09:05 am
- Trius Therapeutics: Outstanding Potential, Discount Price - Seeking Alpha 01.26.12 | 09:01 am
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
